Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1349 • 2019 ACR/ARP Annual Meeting
Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada
Britney Jones¹, Bo Pan ¹, Joanne Homik ², Anthony Russell ², Walter P. Maksymowych ³, Jill Hall ¹ and Stephanie Keeling ¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, Canada, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are inflammatory arthritides associated with significant potential functional disability if not well controlled. We reviewed the baseline demographic…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…
Abstract Number: 1415 • 2019 ACR/ARP Annual Meeting
Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis
Aurelia Luissi¹, Florencia Pierini ², Ignacio Gandino ², Eliana Botta ³, Fernando Brites ³, Laura Boero ³, Maximiliano Martin ³, Tomas Meroño ³, Soledad saez ⁴, Walter Tetzlaff ³, Fernando Sommerfleck ⁵, Gustavo Citera ⁶, Javier Rosa ⁷, Patricia Sorroche ⁴ and Enrique Soriano ⁸, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Capital Federal, Argentina, ³Universidad de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Sanatorio Mendez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁸Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular diseases. Recent studies found that RA patients present dysfunctional high density lipoproteins (HDL)…
Abstract Number: 1770 • 2019 ACR/ARP Annual Meeting
Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation
Chrong-Reen Wang¹, Shih-Yao Chen ¹, Yu-Chi Chou ², Chao-Liang Wu ³, Yu-Ting Lo ¹ and Ai-Li Shiau ⁴, ¹National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ²Genomics Research Center, Academia Sinica, Taipei, Taiwan (Republic of China), ³National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China), ⁴National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China)
Background/Purpose: Long non-coding RNAs (lncRNAs) participate in the rheumatoid arthritis (RA) pathogenesis. The aim of this study was to examine the lncRNA H19 and HOTAIR…
Abstract Number: 1894 • 2019 ACR/ARP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study
Lingyi Li¹, Na Lu ¹, Diane Lacaille ², Hui Xie ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) compared…
Abstract Number: 2015 • 2019 ACR/ARP Annual Meeting
Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients
Urvashi Kaundal ¹, Varun Dhir¹, Biman Saikia ¹ and Aastha Khullar ¹, ¹Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Methotrexate (MTX) is the gold-standard DMARD in rheumatoid arthritis, however, it is unclear how exactly it works. Its effects on neutrophils may involve reduction…
Abstract Number: 2238 • 2019 ACR/ARP Annual Meeting
Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach
George Karpouzas¹, Elizabeth Hernandez ², Lorena Ruiz ³, Vibeke Strand ⁴ and Sarah Ormseth ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, ³Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment of rheumatoid arthritis (RA) to remission optimally ensures control of symptoms, prevention of structural damage, optimization of function and quality of life. Adherence…
Abstract Number: 2308 • 2019 ACR/ARP Annual Meeting
The Interaction Between Human Leukocyte Antigen Class II Alleles and Seroprotection to Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A post-hoc Analysis
Miriam Kim ¹, Jin Kyun Park ², Eun Bong Lee ³ and Kichul Shin⁴, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ⁴Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea., seoul, Republic of Korea
Background/Purpose: There are few studies that have looked into the role of human leukocyte antigen (HLA) class II alleles in seroprotection to influenza, especially in…
Abstract Number: 2328 • 2019 ACR/ARP Annual Meeting
In Rheumatoid Arthritis, New-onset Prednisone Use Is Associated with a Daily Dose, Cumulative Dose, and Duration-dependent Risk for Cardiovascular Events at 6 Months and 1 Year of Use
Anthony Ocon¹, George Reed ² and Joel Kremer ³, ¹University of Rochester Medical Center, Rochester, NY, ²Corrona Research Foundation, Waltham, MA, ³Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease but also affects the cardiovascular (CV) system. Many patients are treated with corticosteroids. Corticosteroid use…
Abstract Number: 2348 • 2019 ACR/ARP Annual Meeting
KL-6 Is a Useful Marker to Monitor the Progression of RA-ILD, but Not to Diagnose or Predict the Development of ILD
Yuta Takamura¹, Ayae Tanaka ¹, Kazuhiro Kurasawa ¹, Anna Hasegawa ², Chika Hiyama ², Toshiyuki Miyao ¹, Ryutaro Yamazaki ¹, Satoko Arai ¹, Takayoshi Owada ¹, Reika Maezawa ¹ and Masafumi Arima ², ¹Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi, Japan, ²Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: Interstitial lung disease (ILD) is a critical　comorbidity in RA. To manage RA-ILD, early diagnosis and monitoring disease progression are important. KL-6 is a marker…
Abstract Number: 2374 • 2019 ACR/ARP Annual Meeting
MRI of the Wrist in Early Rheumatoid Arthritis After 1-year Treat-to-target Strategy
Fan Xiao¹, Jacky Ka Ko ¹, Jiang Yue ¹, James Griffith ¹ and Lai-Shan Tam ¹, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Background:There are two types of remission in rheumatoid arthritis. The first, and most commonly applied, is clinical remission. Imaging remission is another aspect to…
Abstract Number: 2405 • 2019 ACR/ARP Annual Meeting
Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis
Jian Chen ¹, Meng-shi Tang ², Li-chang Xu ³, Shu Li ², Yan Ge ², Jing Tian ², Xi Xie ², Jin-wei Chen ², Jin-feng Du ² and Fen Li¹, ¹Department of Rheumatology and Immunology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China, Changsha, ²Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, ³International Department of YALI High School, Changsha
Background/Purpose: Patients with rheumatoid arthritis (RA) usually receive triple therapy with methotrexate (MTX), leflunomide (LEF) and infliximab (IFX), but nearly one-third of them do not…
Abstract Number: 2824 • 2019 ACR/ARP Annual Meeting
Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)
Navraj Nagra¹, Danielle Robinson ², Antonella Delmestri ¹, Stephanie Dakin ¹, Sarah Snelling ¹, Andrew Carr ¹ and Daniel Prieto-Alhambra ¹, ¹University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: The microbiome and specific bacterial triggers have been hypothesised to be involved in the pathogenesis of Rheumatoid Arthritis (RA) and RA flares. Antibiotic usage…
Abstract Number: 49 • 2019 ACR/ARP Annual Meeting
Towards a Single Cell Portrait of Rheumatoid Arthritis – Development of a Single Cell Multiomics Pipeline for Phase 2 of the Accelerating Medicine Partnership (AMP) – RA Network
Kevin Wei¹, Anna Helena Jonsson ¹, Fan Zhang ², Aparna Nathan ³, Joseph Mears ², Gerald Watts ², Zhu Zhu ², ilya Korsunsky ², Laura Donlin ⁴, Deepak Rao ², Andrew Filer ⁵, Accelerating Medicine Partnership (AMP) ⁶, Brendan Boyce ⁷, Ellen Gravallese ⁸, V. Michael Holers ⁹, Larry Moreland ¹⁰, Peter Gregersen ¹¹, Vivian Bykerk ¹², Jennifer Anolik ⁷, Soumya Raychaudhuri ² and Michael Brenner ¹³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Hospital For Special Surgery, New York, NY, ⁵Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom, ⁶Brigham and Women's Hospital, Boston, ⁷University of Rochester Medical Center, Rochester, NY, ⁸University of Massachusetts Medical School, Worcester, MA, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ¹⁰University of Pittsburgh, PITTSBURGH, PA, ¹¹Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Hospital for Special Surgery, New York City, NY, ¹³Brigham and Women’s Hospital:, Boston
Background/Purpose: The goal of the Accelerating Medicines Partnership (AMP) program is to study synovial tissue from individuals with rheumatoid arthritis (RA) using high-dimensional analyses. During…
Abstract Number: 183 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Data-driven principal component (PC) and cluster analysis has the potential to identify previously unknown patient subgroups within a rheumatoid arthritis (RA) registry to establish…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].